Skip to main content

Bladder Cancer Clinical Trials

Review the bladder cancer clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 174

Testing the Role of DNA Released from Tumor Cells into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
Status: Active
Location: 467 locations
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) with One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Status: Active
Location: 475 locations
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
Status: Active
Location: 211 locations
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
Status: Active
Location: 122 locations
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
Status: Active
Location: 113 locations
Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy
Status: Active
Location: 55 locations
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
Status: Active
Location: 24 locations
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
Status: Active
Location: 16 locations
A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC)
Status: Active
Location: 16 locations
A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer
Status: Active
Location: 15 locations
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
Status: Active
Location: 14 locations
A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma
Status: Active
Location: 12 locations
A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults With HR+ Breast Cancer and Other Select Solid Tumors
Status: Active
Location: 11 locations
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
Status: Active
Location: 10 locations
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
Status: Active
Location: 10 locations
Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer
Status: Active
Location: 8 locations
A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer
Status: Active
Location: 9 locations
Enfortumab Vedotin and Pembrolizumab for the Treatment of Locally Advanced and/or Node Positive Urothelial Cancer, The EV-ECLIPSE Trial
Status: Active
Location: 8 locations
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Status: Active
Location: 9 locations
Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)
Status: Active
Location: 21 locations
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Status: Active
Location: 8 locations
A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer
Status: Active
Location: 8 locations
A Study of 2141-V11 for the Treatment of Bladder Cancer
Status: Active
Location: 7 locations
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
Status: Active
Location: 9 locations
Lattice Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
Status: Active
Location: 7 locations